Tag: CDK4/6Inhibitor

Studies

• Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy Cite
  Jia L, Peng J, Sun N, Chen H, Liu Z, Zhao W, et al. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12621-y
• Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis Cite
  Li X, Niu C, Yi G, Zhang Y, Jin W, Zhang Z, et al. Quercetin inhibits the epithelial-mesenchymal transition and reverses CDK4/6 inhibitor resistance in breast cancer by regulating circHIAT1/miR-19a-3p/CADM2 axis. PLOS ONE. Public Library of Science (PLoS); 2024; 19:e0305612 10.1371/journal.pone.0305612
• Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients Cite
  Lai J, Kuo T, Huang K, Chai LMX, Lee M, Liu C, et al. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The Oncologist. Oxford University Press (OUP); 2023; 29:e455-e466 10.1093/oncolo/oyad304
• Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort Cite
  Pla H, Felip E, Obadia V, Pernas S, Viñas G, Margelí M, et al. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2024; 10.1007/s12094-024-03399-3
• Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study Cite
  Blum JL, DiCristo C, Gordon D, Karuturi MS, Oubre D, Jepsen E, et al. Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07145-1
• Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma Cite
  Hensing WL, Xiu J, Korn WM, Graff SL, Kang I, Torres ETR, et al. Abstract P3-05-08: Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P3-05-08-P3-05-08 10.1158/1538-7445.sabcs22-p3-05-08
• The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations Cite
  Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. Cancers. MDPI AG; 2023; 15:808 10.3390/cancers15030808
• Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer Cite
  Alvarez A, Bernal AM, Anampa J. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06847-2
• CDK4: a master regulator of the cell cycle and its role in cancer Cite
  Baker SJ, Poulikakos PI, Irie HY, Parekh S, Reddy EP. CDK4: a master regulator of the cell cycle and its role in cancer. Genes & Cancer. Impact Journals, LLC; 2022; 13:21-45 10.18632/genesandcancer.221
• Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer Cite
  Whitaker KD, Wang X, Ascha M, Showalter TN, Lewin HG, Calip GS, et al. Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06701-5
• Molecular dynamics simulation and in vitro evaluation of herb–drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy Cite
  Patil PH, Birangal S, Shenoy GG, Rao M, Kadari S, Wankhede A, et al. Molecular dynamics simulation and in vitro evaluation of herb–drug interactions involving dietary polyphenols and CDK inhibitors in breast cancer chemotherapy. Phytotherapy Research. Wiley; 2022; 10.1002/ptr.7547
• Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice Cite
  Hacking SM, Wang Y. Practical Issues of Ki-67 Evaluation in Breast Cancer Clinical Practice. Journal of Clinical and Translational Pathology. Xia & He Publishing; 2022; 000:000-000 10.14218/jctp.2022.00012
• Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer Cite
  Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2018; 10:175883591879332 10.1177/1758835918793326
• Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools? Cite
  D'Amico P, Cristofanilli M. Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. JCO Oncology Practice. American Society of Clinical Oncology (ASCO); 2022; 18:331-334 10.1200/op.21.00707
• A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer Cite
  Sheffield KM, Peachey JR, Method M, Grimes BR, Brown J, Saverno K, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncology. Future Medicine Ltd; 2022; 10.2217/fon-2022-0310
• FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer Cite
  Royce M, Osgood C, Mulkey F, Bloomquist E, Pierce WF, Roy A, et al. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:1155-1162 10.1200/jco.21.02742
• Therapeutic role of flavonoids and flavones in cancer prevention: Current trends and future perspectives Cite
  Khan AU, Dagur HS, Khan M, Malik N, Alam M, Mushtaque M. Therapeutic role of flavonoids and flavones in cancer prevention: Current trends and future perspectives. European Journal of Medicinal Chemistry Reports. Elsevier BV; 2021;:100010 10.1016/j.ejmcr.2021.100010
• Endocrine therapy with or without CDK4/6 inhibitors in women with hormone-receptor positive breast cancer: What do we know about the effects on cognition? Cite
  Kjoe PRLM, van der Wall E, Schagen SB. Endocrine therapy with or without CDK4/6 inhibitors in women with hormone-receptor positive breast cancer: What do we know about the effects on cognition?. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.08.002
• The Exciting New Field of HER2-Low Breast Cancer Treatment Cite
  Eiger D, Agostinetto E, Saúde-Conde R, de Azambuja E. The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers. MDPI AG; 2021; 13:1015 10.3390/cancers13051015
• Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring Cite
  Leenhardt F, Gracia M, Perrin C, Muracciole-Bich C, Marion B, Roques C, et al. Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring. Poster Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-ps5-16
• The immunomodulatory effects of endocrine therapy in breast cancer Cite
  Huang H, Zhou J, Chen H, Li J, Zhang C, Jiang X, et al. The immunomodulatory effects of endocrine therapy in breast cancer. Journal of Experimental & Clinical Cancer Research. Springer Science and Business Media LLC; 2021; 40 10.1186/s13046-020-01788-4
• Invasive lobular carcinoma of the breast: the increasing importance of this special subtype Cite
  McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Research. Springer Science and Business Media LLC; 2021; 23 10.1186/s13058-020-01384-6
• CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis Cite
  Onesti CE, Jerusalem G. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2020;:1-16 10.1080/14737140.2021.1852934
• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Cite
  Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3987-3998 10.1200/jco.20.02514
• Fasting-mimicking diet and hormone therapy induce breast cancer regression Cite
  Caffa I, Spagnolo V, Vernieri C, Valdemarin F, Becherini P, Wei M, et al. Fasting-mimicking diet and hormone therapy induce breast cancer regression. Nature. Springer Science and Business Media LLC; 2020; 583:620-624 10.1038/s41586-020-2502-7
• Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability Cite
  Dobovišek L, Novak M, Krstanović F, Ferk P, Borštnar S, Turnšek TL, et al. Abstract P3-05-11: Cannabidiol increases potency of tamoxifen in inhibiting breast cancer cell viability. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p3-05-11
• Targeted therapy for breast cancer in older patients Cite
  Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Lago LD. Targeted therapy for breast cancer in older patients. Journal of Geriatric Oncology. Elsevier BV; 2020; 11:380-388 10.1016/j.jgo.2019.05.012
• Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies Cite
  Nayar U, Cohen O, Kapstad C, Cuoco MS, Waks AG, Wander SA, et al. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nature Genetics. Springer Science and Business Media LLC; 2018; 51:207-216 10.1038/s41588-018-0287-5
• Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy Cite
  Warth B, Raffeiner P, Granados A, Huan T, Fang M, Forsberg EM, et al. Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. Cell Chemical Biology. Elsevier BV; 2018; 25:291-300.e3 10.1016/j.chembiol.2017.12.010
• CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer Cite
  Dai M, Zhang C, Ali A, Hong X, Tian J, Lo C, et al. CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2016; 6 10.1038/srep35383
• Cell cycle targeted anticancer drugs; Present and Future Cite
  Kacar O. Cell cycle targeted anticancer drugs; Present and Future. Natural Science and Discovery. Natural Science and Discovery; 2016; 2:1 10.20863/nsd.94129
• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer Cite
  Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2016; 76:2301-2313 10.1158/0008-5472.can-15-0728
• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Cite
  Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. Elsevier BV; 2016; 29:255-269 10.1016/j.ccell.2016.02.006
• Palbociclib: A breakthrough in breast carcinoma in women Cite
  Gupta AK, Sharma S, Dahiya N, Brashier D. Palbociclib: A breakthrough in breast carcinoma in women. Medical Journal Armed Forces India. Elsevier BV; 2016; 72:S37-S42 10.1016/j.mjafi.2015.11.002
• Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order Cite
  Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resistance Updates. Elsevier BV; 2016; 24:13-22 10.1016/j.drup.2015.11.001
• Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway Cite
  Qin G, Xu F, Qin T, Zheng Q, Shi D, Xia W, et al. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget. Impact Journals, LLC; 2015; 6:41794-41808 10.18632/oncotarget.5993